

MONSANTO CO /NEW/  
Form 8-K  
April 10, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): April 7, 2015**

**MONSANTO COMPANY**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-16167**  
**(Commission**  
  
**File Number)**  
**800 North Lindbergh Boulevard**

**43-1878297**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: MONSANTO CO /NEW/ - Form 8-K

**St. Louis, Missouri 63167**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (314) 694-1000**

**Not Applicable**

**(Former Name or Former Address, If Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On April 7, 2015, Monsanto Company (the Company ) entered into an underwriting agreement (the Underwriting Agreement, which term includes the Pricing Agreement attached thereto as Exhibit I) with Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated as representatives of the underwriters named therein (collectively, the Underwriters ), related to the sale by the Company of (i) \$300,000,000 principal amount of its 2.850% Senior Notes due 2025 (the Notes due 2025 ), and (ii) \$500,000,000 principal amount of its 3.950% Senior Notes due 2045 (the Notes due 2045 and, together with the Notes due 2025, the Notes ). The Notes were issued on April 10, 2015 pursuant to an Indenture (the Indenture ), dated as of July 1, 2014, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the Trustee ).

In connection with the offering of the Notes, we are filing this Current Report on Form 8-K to add the following exhibits to the Company's Registration Statement on Form S-3 (File No. 333-197036): (i) the Underwriting Agreement and Pricing Agreement (Exhibit 1.1 to this Current Report on Form 8-K), (ii) the forms of Notes (Exhibits 4.1 and 4.2 to this Current Report on Form 8-K) and (iii) the opinion of counsel with respect to the status of the Notes as binding obligations (Exhibit 5.1 to this Current Report on Form 8-K).

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits*

- 1.1 Underwriting Agreement and Pricing Agreement, dated as of April 7, 2015, by and among Monsanto Company and Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the Underwriters.
- 4.1 Form of 2.850% Note due 2025.
- 4.2 Form of 3.950% Note due 2045.
- 5.1 Opinion of Bryan Cave LLP.
- 23.1 Consent of Bryan Cave LLP (included in Exhibit 5.1).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MONSANTO COMPANY**

Date: April 10, 2015

By: /s/ Jennifer L. Woods  
Name: Jennifer L. Woods  
Title: Assistant Secretary

**EXHIBIT INDEX**

- 1.1 Underwriting Agreement and Pricing Agreement, dated as of April 7, 2015, by and among Monsanto Company and Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the Underwriters.
- 4.1 Form of 2.850% Note due 2025.
- 4.2 Form of 3.950% Note due 2045.
- 5.1 Opinion of Bryan Cave LLP.
- 23.1 Consent of Bryan Cave LLP (included in Exhibit 5.1).